Cu(II)-acylhydrazone complex, a potent and selective antitumor agent against human osteosarcoma: Mechanism of action studies over in vitro and in vivo models

被引:7
作者
Balsa, Lucia M. [1 ]
Solerno, Luisina M. [2 ,3 ]
Rodriguez, Maria R. [1 ]
Parajon-Costa, Beatriz S.
Gonzalez-Baro, Ana C. [1 ]
Alonso, Daniel F. [2 ]
Garona, Juan [2 ,3 ]
Leon, Ignacio E. [1 ,4 ]
机构
[1] Univ Nacl La Plata, Fac Ciencias Exactas, Dept Quim, CEQUINOR UNLP,CCT CONICET La Plata,Asociado CIC, Blvd 120 N 1465, RA-1900 La Plata, Argentina
[2] Univ Nacl Quilmes, Ctr Oncol Mol & Traslac COMTra, Bernal, Argentina
[3] Hosp Alta Complej Red Cruce Dr Nestor Carlos Kirch, Ctr Med Traslac, Unidad 6, Florencio Varela, Argentina
[4] Univ Nacl La Plata, Fac Ciencias Exactas, Dept Ciencias Biol, Catedra Fisiopatol, 47 & 115, RA-1900 La Plata, Argentina
关键词
Cancer; Osteosarcoma; Copper complexes; Mechanism of action; Proteomic approach; In vivo studies; COPPER(II) COMPLEXES; DNA-DAMAGE; CYTOTOXICITY; APOPTOSIS; GENOTOXICITY; METALLODRUGS; MONONUCLEAR; RUTHENIUM; CU(II);
D O I
10.1016/j.cbi.2023.110685
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Osteosarcoma (OS) is a frequent bone cancer, affecting largely children and young adults. Cisplatin (CDDP) has been efficacious in the treatment of different cancer such us OS but the development of chemoresistance and important side effects leading to therapeutic failure. Novel therapies including copper compounds have shown to be potentially effective as anticancer drugs and one alternative to usually employed platinum compounds.The goal of this work is the evaluation of the in vitro and in vivo antitumoral activity and dilucidate the molecular target of a Cu(II) cationic complex containing a tridentate hydrazone ligand, CuHL for short, H2L=N'-'-(2-hydroxy-3-methoxybenzylidene)thiophene-2-carbohydrazide, against human OS MG-63 cells.Anticancer activity on MG-63 cell line was evaluated in OS monolayer and spheroids. CuHL significantly impaired cell viability in both models (IC50 2D: 2.1 +/- 0.3 mu M; 3D: 9.1 +/- 1.0 mu M) (p < 0.001). Additional cell studies demonstrated the copper compound inhibits cell proliferation and conveys cells to apoptosis, determined by flow cytometry. CuHL showed a great genotoxicity, evaluated by comet assay. Proteomic analysis by Orbitrap Mass Spectometry identified 27 differentially expressed proteins: 17 proteins were found overexpressed and 10 underexpressed in MG-63 cells after the CuHL treatment. The response to unfolded protein was the most affected biological process.In addition, in vivo antitumor effects of the compound were evaluated on human OS tumors xenografted in nude mice. CuHL treatment, at a dose of 2 mg/kg i.p., given three times/week for one month, significantly inhibited the progression of OS xenografts and was associated to a reduction in mitotic index and to an increment of tumor necrosis (p < 0.01). Administration of standard-of-care cytotoxic agent CDDP, following the same treatment schedule as CuHL, failed to impair OS growth and progression.
引用
收藏
页数:10
相关论文
共 49 条
[1]   Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy [J].
Abid, Mohammad ;
Shamsi, Farheen ;
Azam, Amir .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2016, 16 (10) :772-786
[2]  
Balsa L.M., 2023, Quantitative Proteomics, P7531
[3]   Copper Complexes as Antitumor Agents: In vitro and In vivo Evidence [J].
Balsa, Lucia M. ;
Baran, Enrique. J. ;
Leon, Ignacio E. .
CURRENT MEDICINAL CHEMISTRY, 2023, 30 (05) :510-557
[4]   Anticancer Activity and Mechanism of Action Evaluation of an Acylhydrazone Cu(II) Complex toward Breast Cancer Cells, Spheroids, and Mammospheres [J].
Balsa, Lucia M. ;
Rodriguez, Maria R. ;
Parajon-Costa, Beatriz S. ;
Gonzalez-Baro, Ana C. ;
Lavecchia, Martin J. ;
Leon, Ignacio E. .
CHEMMEDCHEM, 2022, 17 (04)
[5]   Anticancer activity of a new copper(ii) complex with a hydrazone ligand. Structural and spectroscopic characterization, computational simulations and cell mechanistic studies on 2D and 3D breast cancer cell models [J].
Balsa, Lucia M. ;
Ferraresi-Curotto, Veronica ;
Lavecchia, Martin J. ;
Echeverria, Gustavo A. ;
Piro, Oscar E. ;
Garcia-Tojal, Javier ;
Pis-Diez, Reinaldo ;
Gonzalez-Baro, Ana C. ;
Leon, Ignacio E. .
DALTON TRANSACTIONS, 2021, 50 (28) :9812-9826
[6]   Anticancer and antimetastatic activity of copper(II)-tropolone complex against human breast cancer cells, breast multicellular spheroids and mammospheres [J].
Balsa, Lucia M. ;
Ruiz, Maria C. ;
Santa Maria de la Parra, Lucia ;
Baran, Enrique J. ;
Leon, Ignacio E. .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2020, 204
[7]   Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective [J].
Benjamin, Robert S. .
CURRENT ADVANCES IN OSTEOSARCOMA: CLINICAL PERSPECTIVES: PAST, PRESENT AND FUTURE, 2ND EDITION, 2020, 1257 :1-10
[8]   Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs [J].
Bindoli, Alberto ;
Rigobello, Maria Pia ;
Scutari, Guido ;
Gabbiani, Chiara ;
Casini, Angela ;
Messori, Luigi .
COORDINATION CHEMISTRY REVIEWS, 2009, 253 (11-12) :1692-1707
[9]  
Burgos-Lopez Y., INORG CHIM ACTA
[10]   Tridentate acylhydrazone copper(II) complexes with heterocyclic bases as coligands. Synthesis, spectroscopic studies, crystal structure and cytotoxicity assays [J].
Burgos-Lopez, Yacelis ;
Balsa, Lucia M. ;
Piro, Oscar E. ;
Leon, Ignacio E. ;
Garcia-Tojal, Javier ;
Echeverria, Gustavo A. ;
Gonzalez-Baro, Ana C. ;
Parajon-Costa, Beatriz S. .
POLYHEDRON, 2022, 213